Compare with JAYS.DYESTUF - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GENERIC PHARMASEC vs JAYS.DYESTUF - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GENERIC PHARMASEC JAYS.DYESTUF GENERIC PHARMASEC/
JAYS.DYESTUF
 
P/E (TTM) x 100.1 12.7 785.6% View Chart
P/BV x 10.0 0.8 1,284.2% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 GENERIC PHARMASEC   JAYS.DYESTUF
EQUITY SHARE DATA
    GENERIC PHARMASEC
Mar-21
JAYS.DYESTUF
Mar-21
GENERIC PHARMASEC/
JAYS.DYESTUF
5-Yr Chart
Click to enlarge
High Rs1780 20.8%   
Low Rs723 31.8%   
Sales per share (Unadj.) Rs0.8146.2 0.5%  
Earnings per share (Unadj.) Rs05.2 0.9%  
Cash flow per share (Unadj.) Rs07.3 0.6%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Avg Dividend yield %00.4 0.0%  
Book value per share (Unadj.) Rs0.797.1 0.8%  
Shares outstanding (eoy) m276.868.69 3,186.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x15.60.4 4,414.3%   
Avg P/E ratio x263.59.9 2,657.2%  
P/CF ratio (eoy) x260.97.1 3,679.3%  
Price / Book Value ratio x16.00.5 3,024.9%  
Dividend payout %03.9 0.0%   
Avg Mkt Cap Rs m3,314448 740.5%   
No. of employees `000NANA-   
Total wages/salary Rs m274 2.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m2131,270 16.8%  
Other income Rs m39 35.4%   
Total revenues Rs m2161,279 16.9%   
Gross profit Rs m1275 15.9%  
Depreciation Rs m018 0.7%   
Interest Rs m03 0.0%   
Profit before tax Rs m1563 24.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m318 14.3%   
Profit after tax Rs m1345 27.9%  
Gross profit margin %5.65.9 95.0%  
Effective tax rate %16.728.1 59.5%   
Net profit margin %5.93.6 166.1%  
BALANCE SHEET DATA
Current assets Rs m2681,057 25.3%   
Current liabilities Rs m72306 23.4%   
Net working cap to sales %92.159.2 155.6%  
Current ratio x3.73.5 108.1%  
Inventory Days Days14815 969.8%  
Debtors Days Days128,898,635119,154,210 108.2%  
Net fixed assets Rs m10118 8.7%   
Share capital Rs m2779 3,186.0%   
"Free" reserves Rs m-70835 -8.4%   
Net worth Rs m207844 24.5%   
Long term debt Rs m04 0.0%   
Total assets Rs m2781,176 23.7%  
Interest coverage xNM19.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.81.1 70.9%   
Return on assets %4.54.1 109.3%  
Return on equity %6.15.3 113.8%  
Return on capital %7.37.8 93.6%  
Exports to sales %061.4 0.0%   
Imports to sales %011.9 0.0%   
Exports (fob) Rs mNA779 0.0%   
Imports (cif) Rs mNA151 0.0%   
Fx inflow Rs m0779 0.0%   
Fx outflow Rs m0157 0.0%   
Net fx Rs m0623 0.0%   
CASH FLOW
From Operations Rs m-21-6 335.7%  
From Investments Rs m-1434 -41.1%  
From Financial Activity Rs m4538 117.9%  
Net Cashflow Rs m1066 14.4%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 60.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.1 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 40.0 25.3 158.6%  
Shareholders   17,121 3,218 532.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GENERIC PHARMASEC With:   ASAHI SONGWON  BODAL CHEMICALS  



Today's Market

SGX Nifty Up 47 Points, RBI Monetary Policy Highlights, Airtel's Big Step Towards Broadband Expansion, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note yesterday. The bulls continued to roar on the Dalal Street, as the key benchmark indices logged back-to-back strong gains.

Related Views on News

Ami Organics Stock Makes Impressive Debut on Bourses. Lists at 49% Premium (Views On News)

Sep 14, 2021

Shares of Ami Organics makes a strong debut on the stock exchange. Did you bid for the IPO?

Chemplast Sanmar Makes Flat Debut as IPO Frenzy Fizzles Out (Views On News)

Aug 24, 2021

The grey market had indicated a flat listing for shares of Chemplast Sanmar ahead of its debut.

Understanding Aarti Industries' Demerger (Views On News)

Aug 20, 2021

Will the pharma unit's demerger unlock value for shareholders?

What Next for Devyani, Zomato, & Tatva Chintan Pharma After Stellar IPO Gains? (Views On News)

Aug 20, 2021

What's the outlook for Devyani, Zomato, and Tatva Chintan Pharma after robust listings?

Pidilite Results Review: Net Profit Spikes as Sales Rise 121% (Views On News)

Aug 12, 2021

Pidilite posts strong sales growth and a multi-fold jump in bottomline.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

6 Penny Stocks that Rallied 1,000%+ in One Year(Views On News)

Dec 6, 2021

These penny stocks shed their penny status by surging 1,000% or more in the last one year.

The Biggest Winners and Losers in India's Transition to Electric Vehicles(Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GENERIC PHARMASEC SHARE PRICE


Dec 9, 2021 09:21 AM

TRACK GENERIC PHARMASEC

  • Track your investment in GENERIC PHARMASEC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GENERIC PHARMASEC

GENERIC PHARMASEC 8-QTR ANALYSIS

COMPARE GENERIC PHARMASEC WITH

MARKET STATS